Welcome to our dedicated page for Cosmos Health news (Ticker: COSM), a resource for investors and traders seeking the latest updates and insights on Cosmos Health stock.
Cosmos Health Inc. (NASDAQ: COSM) generates a steady flow of news across pharmaceuticals, nutraceuticals, healthcare services and digital assets, reflecting its description as a diversified, vertically integrated global healthcare group. News coverage often highlights developments in its proprietary brands, EU-based manufacturing operations, distribution activities, research and development programs, telehealth initiatives and financing arrangements.
Recent press releases have focused on record quarterly financial results, including revenue growth and margin expansion attributed to contract manufacturing at Cana Laboratories, UK distribution through Decahedron, the CosmoFarm distribution business, and global expansion of brands such as Sky Premium Life and C-Sept/C-Scrub. Coverage has also included manufacturing agreements, such as the PathMuscle production agreement through Cana Laboratories, which illustrates the company’s role as a pharmaceutical manufacturing partner.
Investors following COSM news will also see updates on Cosmos Health’s R&D pipeline, including programs like CCX0722 for obesity and weight management and other repurposed compounds targeting major disorders. News items describe how these efforts are supported by the Cloudscreen AI-enabled drug repurposing platform and by initiatives in nanotechnology to develop next-generation nutraceutical formulas.
Beyond core healthcare operations, Cosmos Health issues news about its digital asset strategy, including Ethereum purchases under a $300 million facility and a strategic partnership with Prime Ledger LLC to manage digital asset treasury operations and tokenize intellectual property. Regulatory and capital markets updates, such as Nasdaq listing compliance notices, financing transactions involving senior secured convertible notes, and shareholder meeting outcomes, also feature prominently.
For readers tracking COSM, this news stream provides insight into how the company is executing across manufacturing, distribution, R&D, telehealth and digital finance. Regular updates help contextualize financial performance, strategic partnerships and regulatory milestones that shape Cosmos Health’s trajectory.
Cosmos Holdings has launched King Eros and Queen Venus, nutritional supplements aimed at enhancing sexual health for men and women, respectively. These products are being introduced in approximately 1,700 pharmacies in Greece and selected stores in Cyprus, with plans for an additional 1,500 pharmacies by year-end. The company aims for international expansion into the UK, Germany, Canada, and China. Both products are crafted following GMP standards, reflecting quality and safety. CEO Greg Siokas emphasizes strong market demand for these health supplements.
Cosmos Holdings has launched Mosept-Oral, a proprietary oral antiseptic spray targeting bacterial and viral throat infections. Initially available in 3,500 pharmacies in Greece, the company aims to expand to 10,000 pharmacies by year-end. The product contains Chlorhexidine and Lidocaine for sore throat relief and is being registered for sales in various European and Middle Eastern markets. Research suggests its effectiveness against SARS-CoV-2, encouraging potential for broader applications in pandemic health measures.
Cosmos Holdings (OTCQX: COSM) has launched a new dietary supplement, Osteodome, designed to enhance bone, cartilage health, and joint flexibility. The product is part of the Sky Premium Life line and targets normal bone function and muscle performance. Following the recent expansion of its EU distribution network to 1,500 pharmacies, the company anticipates Osteodome to significantly contribute to growth and profitability in 2021. The launch follows a previous product release, Bodyguard, aimed at bolstering immune health during the ongoing pandemic.
Cosmos Holdings has appointed Peter Goldstein to its Board of Directors and entered into an advisory agreement with PGS Ventures B.V. to assist in mergers and acquisitions and strategic planning. Goldstein brings over 30 years of experience in international business, including successful IPOs and mergers. His role will focus on evaluating potential acquisition targets to boost top-line revenues and EBITDA, with a goal of uplisting Cosmos Holdings to a senior exchange. The company aims to leverage his expertise to enhance shareholder value.